세계의 알츠하이머 치료제 시장 보고서(2023년)

“Alzheimer's Drugs Global Market Report 2023 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on alzheimer's drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for alzheimer's drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The alzheimer's drugs market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

• 1) By Drugs: Donepezil; Rivastigmine; Galantamine; Memantine

• 2) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy

• 3) By Application: Early To Moderate Stages; Moderate To Severe Stages

• Companies Mentioned: Abbvie Inc.; Daiichi Sankyo Company Limited; F. Hoffmann-La Roche AG; Merck & Co. Inc.; Novartis AG

• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA

• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

• Time series: Five years historic and ten years forecast.

• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,

• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.

• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

• Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Major players in the Alzheimer's drugs market are Abbvie Inc., Daiichi Sankyo Company Limited, F. Hoffmann-La Roche AG, Merck & Co. Inc., Novartis AG, Biogen Inc., AstraZeneca PLC., Eisai Co. Ltd., Eli Lilly and Company, H. Lundbeck A/S, Pfizer Inc., Allergan PLC., Johnson & Johnson, Lupin Pharmaceuticals Inc., and Actiza Pharmaceutical Private Limited.

The global Alzheimer's drugs market is expected to grow from $7.90 billion in 2022 to $8.60 billion in 2023 at a compound annual growth rate (CAGR) of 8.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The Alzheimer's drugs market is expected to reach $11.85 billion in 2027 at a CAGR of 8.3%.

The Alzheimer's drugs market consists of sales of cholinesterase inhibitors such as aricept, exelon, and razadyne. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Alzheimer's drugs refer to drugs that aid in managing memory loss, issues with thinking and reasoning, and daily functioning. These drugs are used to treat Alzheimer's disease, a brain disorder that causes memory, reasoning, and learning to gradually diminish.

North America was the largest region in the Alzheimer's drugs market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The major drugs for Alzheimer's are donepezil, rivastigmine, galantamine, and memantine. The drug donepezil refers to a member of the class of drugs known as cholinesterase inhibitors. These are sold through several distribution channels, such as hospital pharmacies, retail pharmacies, and online pharmacies, and are used in several applications, such as early to moderate stages and moderate to severe stages.

The rising prevalence of Alzheimer's disease is expected to propel the growth of the Alzheimer's drugs market going forward. Alzheimer's disease is a neurologic condition that worsens over time and causes both brain shrinkage and cell death. Drugs for Alzheimer's disease are used to treat memory loss, problems with thinking and reasoning, and difficulties with everyday living. Drugs for Alzheimer's can enhance the quality of life and help maintain independence. For instance, in June 2020, according to the 2022 Alzheimer's Disease Facts and Figures report by The Alzheimer's Association, a US-based non-profit and voluntary health organization in Alzheimer's care, support and research. In 2022, there were 6.5 million Americans 65 and older who have Alzheimer's disease. About 1 in 9 Americans (or 10.7% of the total population) who are 65 or older have Alzheimer's disease. The percentage of those who have Alzheimer's disease rises with age: 5.0% of those between the ages of 65 and 74, 13.1% of those between the ages of 75 and 84, and 33.2% of those beyond the age of 85. By 2050, there are expected to be 88 million Americans aged 65 and older, up from 58 million in 2021. Therefore, the increasing prevalence of Alzheimer's disease is driving the growth of the Alzheimer's drugs market.

Technological advancements have emerged as a key trend gaining popularity in the Alzheimer's disease market. Major companies operating in the Alzheimer's disease market are focused on innovating new technologies to sustain their position in the market. For instance, in January 2021, iMediSync, a South Korea-based healthcare platform company, launched iSyncBrain, an EEG digital biomarker for early Alzheimer's dementia diagnosis on their AI cloud platform. They also provide customized NIR-LED neuromodulation using their future cutting-edge headset, iSyncWaveTM, to increase neural activity, employing AI analytics and brain mapping techniques. To prevent dementia in the preclinical stage, the iSyncBrain® MCI classifier screens and distinguishes between amnestic moderate cognitive impairment (MCI) of the Alzheimer or non-Alzheimer type. This has undergone multicenter clinical testing with over 90% accuracy rates.

In March 2022, AbbVie, a US-based publicly traded biopharmaceutical company, acquired Syndesi Therapeutics for an undisclosed amount. This acquisition grants AbbVie access to Syndesi's portfolio of new modulators of the synaptic vesicle protein 2A (SV2A), including its lead compound SDI-118, and will aid in the expansion of AbbVie's neuroscience product line. Syndesis Therapeutics is a Belgium-based company that treats Alzheimer's disease and other disorders with cognitive impairment.

The countries covered in the Alzheimer's drugs market report are: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The Alzheimer's drugs market research report is one of a series of new reports from The Business Research Company that provides Alzheimer's drugs market statistics, including Alzheimer's drugs industry global market size, regional shares, competitors with a Alzheimer's drugs market share, detailed Alzheimer's drugs market segments, market trends and opportunities, and any further data you may need to thrive in the Alzheimer's drugs industry. This Alzheimer's drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Table of Contents

1. Executive Summary

2. Alzheimer's Drugs Market Characteristics

3. Alzheimer's Drugs Market Trends And Strategies

4. Alzheimer's Drugs Market - Macro Economic Scenario

• 4.1. COVID-19 Impact On Alzheimer's Drugs Market
• 4.2. Ukraine-Russia War Impact On Alzheimer's Drugs Market
• 4.3. Impact Of High Inflation On Alzheimer's Drugs Market

5. Alzheimer's Drugs Market Size And Growth

• 5.1. Global Alzheimer's Drugs Historic Market, 2017-2022, $ Billion
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints On The Market
• 5.2. Global Alzheimer's Drugs Forecast Market, 2022-2027F, 2032F, $ Billion
  • 5.2.1. Drivers Of The Market
  • 5.2.2. Restraints On the Market

6. Alzheimer's Drugs Market Segmentation

• 6.1. Global Alzheimer's Drugs Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• Donepezil
• Rivastigmine
• Galantamine
• Memantine
• 6.2. Global Alzheimer's Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• 6.3. Global Alzheimer's Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• Early To Moderate Stages
• Moderate To Severe Stages

7. Alzheimer's Drugs Market Regional And Country Analysis

• 7.1. Global Alzheimer's Drugs Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 7.2. Global Alzheimer's Drugs Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

8. Asia-Pacific Alzheimer's Drugs Market

• 8.1. Asia-Pacific Alzheimer's Drugs Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Alzheimer's Drugs Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 8.3. Asia-Pacific Alzheimer's Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

9. China Alzheimer's Drugs Market

• 9.1. China Alzheimer's Drugs Market Overview
• 9.2. China Alzheimer's Drugs Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion
• 9.3. China Alzheimer's Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion

10. India Alzheimer's Drugs Market

• 10.1. India Alzheimer's Drugs Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 10.2. India Alzheimer's Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

11. Japan Alzheimer's Drugs Market

• 11.1. Japan Alzheimer's Drugs Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 11.2. Japan Alzheimer's Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

12. Australia Alzheimer's Drugs Market

• 12.1. Australia Alzheimer's Drugs Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 12.2. Australia Alzheimer's Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

13. Indonesia Alzheimer's Drugs Market

• 13.1. Indonesia Alzheimer's Drugs Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 13.2. Indonesia Alzheimer's Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

14. South Korea Alzheimer's Drugs Market

• 14.1. South Korea Alzheimer's Drugs Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 14.2. South Korea Alzheimer's Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

15. Western Europe Alzheimer's Drugs Market

• 15.1. Western Europe Alzheimer's Drugs Market Overview
• 15.2. Western Europe Alzheimer's Drugs Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 15.3. Western Europe Alzheimer's Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

16. UK Alzheimer's Drugs Market

• 16.1. UK Alzheimer's Drugs Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 16.2. UK Alzheimer's Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

17. Germany Alzheimer's Drugs Market

• 17.1. Germany Alzheimer's Drugs Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 17.2. Germany Alzheimer's Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

18. France Alzheimer's Drugs Market

• 18.1. France Alzheimer's Drugs Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 18.2. France Alzheimer's Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

19. Eastern Europe Alzheimer's Drugs Market

• 19.1. Eastern Europe Alzheimer's Drugs Market Overview
• 19.2. Eastern Europe Alzheimer's Drugs Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 19.3. Eastern Europe Alzheimer's Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

20. Russia Alzheimer's Drugs Market

• 20.1. Russia Alzheimer's Drugs Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 20.2. Russia Alzheimer's Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

21. North America Alzheimer's Drugs Market

• 21.1. North America Alzheimer's Drugs Market Overview
• 21.2. North America Alzheimer's Drugs Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 21.3. North America Alzheimer's Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

22. USA Alzheimer's Drugs Market

• 22.1. USA Alzheimer's Drugs Market Overview
• 22.2. USA Alzheimer's Drugs Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 22.3. USA Alzheimer's Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

23. South America Alzheimer's Drugs Market

• 23.1. South America Alzheimer's Drugs Market Overview
• 23.2. South America Alzheimer's Drugs Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 23.3. South America Alzheimer's Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

24. Brazil Alzheimer's Drugs Market

• 24.1. Brazil Alzheimer's Drugs Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 24.2. Brazil Alzheimer's Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

25. Middle East Alzheimer's Drugs Market

• 25.1. Middle East Alzheimer's Drugs Market Overview
• 25.2. Middle East Alzheimer's Drugs Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 25.3. Middle East Alzheimer's Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

26. Africa Alzheimer's Drugs Market

• 26.1. Africa Alzheimer's Drugs Market Overview
• 26.2. Africa Alzheimer's Drugs Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
• 26.3. Africa Alzheimer's Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

27. Alzheimer's Drugs Market Competitive Landscape And Company Profiles

• 27.1. Alzheimer's Drugs Market Competitive Landscape
• 27.2. Alzheimer's Drugs Market Company Profiles
  • 27.2.1. Abbvie Inc
    • 27.2.1.1. Overview
    • 27.2.1.2. Products and Services
    • 27.2.1.3. Strategy
    • 27.2.1.4. Financial Performance
  • 27.2.2. Daiichi Sankyo Company Limited
    • 27.2.2.1. Overview
    • 27.2.2.2. Products and Services
    • 27.2.2.3. Strategy
    • 27.2.2.4. Financial Performance
  • 27.2.3. F. Hoffmann-La Roche AG
    • 27.2.3.1. Overview
    • 27.2.3.2. Products and Services
    • 27.2.3.3. Strategy
    • 27.2.3.4. Financial Performance
  • 27.2.4. Merck & Co. Inc
    • 27.2.4.1. Overview
    • 27.2.4.2. Products and Services
    • 27.2.4.3. Strategy
    • 27.2.4.4. Financial Performance
  • 27.2.5. Novartis AG
    • 27.2.5.1. Overview
    • 27.2.5.2. Products and Services
    • 27.2.5.3. Strategy
    • 27.2.5.4. Financial Performance

28. Key Mergers And Acquisitions In The Alzheimer's Drugs Market

29. Alzheimer's Drugs Market Future Outlook and Potential Analysis

30. Appendix

• 30.1. Abbreviations
• 30.2. Currencies
• 30.3. Historic And Forecast Inflation Rates
• 30.4. Research Inquiries
• 30.5. The Business Research Company
• 30.6. Copyright And Disclaimer